Skip to main content
Top
Published in: Pharmaceutical Medicine 3/2022

Open Access 01-06-2022 | Cholecystitis | Current Opinion

Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets

Authors: Rani Lill Anjum, Rebecca E Chandler, Elena Rocca

Published in: Pharmaceutical Medicine | Issue 3/2022

Login to get access

Abstract

A new approach is proposed for assessing causality in pharmacovigilance. The Dx3 approach is designed to qualitatively evaluate three types of dispositions when assessing whether a particular medicine has or could have caused a certain adverse event. These are: the drug disposition; the pre-disposition of the patient taking the drug (vulnerability) and; the disposition of the patient–drug interaction (mutuality). Each of these three types of dispositions will represent valuable causally relevant evidence for assessing a potential signal of harm. A checklist is provided to guide the assessment of causality for both single individual case safety reports (ICSRs) and case series. Different types of causal information are ranked according to how well suited they are for establishing a disposition. Two case examples are used to demonstrate how the approach can be used in practice for assessment purposes. One aim of the approach is to offer a qualitative way to assess causality and to make the reasoning of different assessors more transparent. A second aim is to encourage the collection of more qualitatively rich patient narratives in the ICSRs. Crucially, we believe this approach can support the inclusion of the single ICSR as a valid and valuable form of evidence.
Literature
1.
go back to reference Edwards IR. Causality assessment in pharmacovigilance: still a challenge. Drug Saf. 2017;40:365–72.CrossRef Edwards IR. Causality assessment in pharmacovigilance: still a challenge. Drug Saf. 2017;40:365–72.CrossRef
2.
go back to reference Mumford S, Anjum RL. Getting causes from powers. Oxford: Oxford University Press; 2011.CrossRef Mumford S, Anjum RL. Getting causes from powers. Oxford: Oxford University Press; 2011.CrossRef
3.
go back to reference Rocca E, Anjum RL, Mumford S. Causal insights from failure. In: La Caze A, Osimani B, editors. Uncertainty in pharmacology: epistemology, methods and decisions. Boston: Springer; 2020. p. 39–57.CrossRef Rocca E, Anjum RL, Mumford S. Causal insights from failure. In: La Caze A, Osimani B, editors. Uncertainty in pharmacology: epistemology, methods and decisions. Boston: Springer; 2020. p. 39–57.CrossRef
4.
go back to reference Anjum RL, Rocca E. From ideal to real risk: philosophy of causation meets risk analysis. Risk Anal. 2019;39:729–40.CrossRef Anjum RL, Rocca E. From ideal to real risk: philosophy of causation meets risk analysis. Risk Anal. 2019;39:729–40.CrossRef
6.
go back to reference Anjum RL, Mumford S. Causation in science and the methods of scientific discovery. Oxford: Oxford University Press; 2018.CrossRef Anjum RL, Mumford S. Causation in science and the methods of scientific discovery. Oxford: Oxford University Press; 2018.CrossRef
8.
go back to reference Cartwright N. Nature’s capacities and their measurements. Oxford: Oxford University Press; 1989. Cartwright N. Nature’s capacities and their measurements. Oxford: Oxford University Press; 1989.
9.
go back to reference Russo F, Williamson J. Interpreting causality in the health sciences. Int Stud Philos Sci. 2007;21:157–70.CrossRef Russo F, Williamson J. Interpreting causality in the health sciences. Int Stud Philos Sci. 2007;21:157–70.CrossRef
10.
go back to reference Maziarz M. Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions? Stud Hist Philos Sci. 2022;91:159–67.CrossRef Maziarz M. Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions? Stud Hist Philos Sci. 2022;91:159–67.CrossRef
12.
go back to reference McLeod J. Why it is important to look closely at what happens when therapy clients complete symptom measures. Philos Psychiatr Psychol. 2021;28:133–6.CrossRef McLeod J. Why it is important to look closely at what happens when therapy clients complete symptom measures. Philos Psychiatr Psychol. 2021;28:133–6.CrossRef
13.
go back to reference Low M. A novel clinical framework: the use of dispositions in clinical practice. A person centred approach. J Eval Clin Pract. 2017;23:1062–70.CrossRef Low M. A novel clinical framework: the use of dispositions in clinical practice. A person centred approach. J Eval Clin Pract. 2017;23:1062–70.CrossRef
14.
go back to reference Gustum LT. The relevance of dispositionalism for psychotherapy and psychotherapy research. In: Anjum LR, Copeland S, Rocca E, editors. Rethinking Causality, complexity and evidence for the unique patient. Dordrecht: Springer Nature; 2020. p. 179–200. Gustum LT. The relevance of dispositionalism for psychotherapy and psychotherapy research. In: Anjum LR, Copeland S, Rocca E, editors. Rethinking Causality, complexity and evidence for the unique patient. Dordrecht: Springer Nature; 2020. p. 179–200.
17.
go back to reference Oosterhuis I, Zweers P, Rümke H, Muller-Hansma A, van Puijenbroek E. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines. Pharmacoepidemiol Drug Saf. 2019;28:544–50.CrossRef Oosterhuis I, Zweers P, Rümke H, Muller-Hansma A, van Puijenbroek E. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines. Pharmacoepidemiol Drug Saf. 2019;28:544–50.CrossRef
18.
go back to reference Meyboom R, Egberts A, Edwards I. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16:355–65.CrossRef Meyboom R, Egberts A, Edwards I. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16:355–65.CrossRef
19.
go back to reference Anjum RL, Copeland S, Rocca E. Medical scientists and philosophers worldwide appeal to EBM to expand the notion of ‘evidence.’ BMJ Evid Based Med. 2018;2018:bmjebm-2018-111092. Anjum RL, Copeland S, Rocca E. Medical scientists and philosophers worldwide appeal to EBM to expand the notion of ‘evidence.’ BMJ Evid Based Med. 2018;2018:bmjebm-2018-111092.
20.
go back to reference European Medicines Agency. Tasigna, INN-nilotinib, Scientific discussion. 2007. European Medicines Agency. Tasigna, INN-nilotinib, Scientific discussion. 2007.
22.
go back to reference Baudou E, Lespine A, Durrieu G, André F, Gandia P, Durand C, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. New Engl. 2020;383:787–9.CrossRef Baudou E, Lespine A, Durrieu G, André F, Gandia P, Durand C, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. New Engl. 2020;383:787–9.CrossRef
23.
go back to reference Mealey K, Bentjen S, Gay J, Cantor G. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 2001;11:727–33.CrossRef Mealey K, Bentjen S, Gay J, Cantor G. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 2001;11:727–33.CrossRef
Metadata
Title
Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets
Authors
Rani Lill Anjum
Rebecca E Chandler
Elena Rocca
Publication date
01-06-2022
Publisher
Springer International Publishing
Published in
Pharmaceutical Medicine / Issue 3/2022
Print ISSN: 1178-2595
Electronic ISSN: 1179-1993
DOI
https://doi.org/10.1007/s40290-022-00429-9

Other articles of this Issue 3/2022

Pharmaceutical Medicine 3/2022 Go to the issue